Drug Co. Investors File Class-Action Against SAC

Jan 3 2013 | 11:44am ET

The Securities and Exchange Commission hasn't sued SAC Capital Advisors yet, but some investors in a pharmaceutical company linked to the insider-trading scandal at the firm aren't waiting.

Six Elan Corp. investors sued the hedge fund late last month, claiming losses due to SAC's allegedly illicit trading in Elan shares. The would-be class-action seeks to represent anyone who traded in Elan American depositary receipts or options from July 21 to 29, 2008.

Elan is one of two companies that former SAC portfolio manager Mathew Martoma is alleged to have illegally traded while at the hedge fund. Martoma was charged in November with getting confidential information about Alzheimer's drug trials and using it to trade in Elan and Wyeth LLC shares.

Prosecutors have called the case against Martoma the "most lucrative" insider-trading scheme in history; they are reportedly seeking Martoma's cooperation in building a case against SAC founder Steven Cohen.

The class-action lawsuit, filed by New York law firm Wohl & Fruchter, names SAC, Cohen, two SAC units, Martoma and Sidney Gilman, Martoma's alleged source. SAC would not comment on the lawsuit but has previously said that it and Cohen acted appropriately.


In Depth

GSAM's Papagiannis: Liquid Alternatives For The Long Run

Apr 21 2017 | 8:44pm ET

Interest in liquid alternatives cooled a bit last year amid a broad shift in investor...

Lifestyle

Aston Martin Returns To Debt Market As DB11 Drives Turnaround

Mar 31 2017 | 5:21pm ET

James Bond’s preferred carmaker is returning to the public debt markets for the...

Guest Contributor

Debunking Conventional Investment Wisdom (Part II)

Apr 17 2017 | 5:56pm ET

The alternative investment industry is currently replete with buzzwords around data...